Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accounts Payables (2020 - 2025)

Tarsus Pharmaceuticals has reported Accounts Payables over the past 6 years, most recently at $101.5 million for Q4 2025.

  • Quarterly results put Accounts Payables at $101.5 million for Q4 2025, up 83.36% from a year ago — trailing twelve months through Dec 2025 was $101.5 million (up 83.36% YoY), and the annual figure for FY2025 was $101.5 million, up 83.36%.
  • Accounts Payables for Q4 2025 was $101.5 million at Tarsus Pharmaceuticals, down from $103.5 million in the prior quarter.
  • Over the last five years, Accounts Payables for TARS hit a ceiling of $103.5 million in Q3 2025 and a floor of $8.1 million in Q3 2021.
  • Median Accounts Payables over the past 5 years was $13.1 million (2022), compared with a mean of $34.1 million.
  • Biggest five-year swings in Accounts Payables: decreased 16.25% in 2023 and later surged 360.15% in 2024.
  • Tarsus Pharmaceuticals' Accounts Payables stood at $8.7 million in 2021, then rose by 14.17% to $9.9 million in 2022, then skyrocketed by 139.06% to $23.7 million in 2023, then skyrocketed by 133.72% to $55.4 million in 2024, then soared by 83.36% to $101.5 million in 2025.
  • The last three reported values for Accounts Payables were $101.5 million (Q4 2025), $103.5 million (Q3 2025), and $78.6 million (Q2 2025) per Business Quant data.